Series C1 · Biotech
Oricell Therapeutics: Series C1
Develops next-generation cell therapies for solid tumors and hematologic malignancies
Funding history
Series C1 · This round$70M
Develops next-generation cell therapies for solid tumors and hematologic malignancies